05/05/2025
We are delighted to announce that Ms. Annamaria Minicozzi, Lead for Colore**al Cancer and the Multidisciplinary Team (MDT) at the Royal London Hospital, Barts Health NHS Trust, has recently received the following prestigious recognitions:
Barts Charity Individual Champion Award at the 2025 Barts Health Heroes Awards, in recognition of her exceptional commitment to surgery and the care of oncology patients, particularly for her expertise in CRS & .
Paul Harris Fellowship, the highest honor bestowed by Rotary International, awarded for her outstanding contributions to charity and the community with her medical work , reflecting the Rotarian principle of "service above self."
Ms. Minicozzi has a long and distinguished career in colore**al cancer care, beginning as a surgical trainee at Verona University Hospital in Italy. Her expertise has expanded through completing an International Colore**al Surgical Oncology Fellowship focused on Organ Preservation/Watch & Wait in re**al cancer at São Paulo, Brazil, followed by a second International Colore**al Fellowship in advanced and recurrent re**al cancer at the Karolinska Hospital in Stockholm, Sweden. In 2010, she earned a PhD for her work on multimodal imaging in colore**al cancer, and in 2014, she was named a Fellow of the Royal College of Surgeons of England.
Ms. Minicozzi's professional journey includes her appointment as Consultant Colore**al and Peritoneal Surgeon at The Christie NHS Foundation Trust in Manchester in 2016, where she performed a high volume of complex colore**al cancer surgeries, including Cytoreductive Surgery (CRS) & Heated Intraperitoneal Chemotherapy (HIPEC), as well as exenterative surgeries. In 2018, she joined the Royal London Hospital where she is the Colore**al Cancer and MDT Lead, and Lead of the Multidisciplinary Peritoneal Oncology Service. Most recently, she is working on a program for Hyperthermic Intrathoracic Perfusion ( ) for pleural malignancies.
Ms. Minicozzi’s clinical and academic interests are centered around advanced and innovative therapies for colore**al cancer, particularly those that address complex cases. She has been instrumental in establishing the CRS & service for peritoneal metastases from colore**al and appendiceal cancers.
Our collaboration with Ms. Minicozzi began in Verona, where she was already pioneering her local CRS & program. Over the years, we have been fortunate to continue this partnership, and we are grateful for the trust she has placed in our collaboration as we have jointly developed new projects in the UK.
We extend our heartfelt congratulations to Ms. Minicozzi for these well-deserved recognitions and look forward to continuing our work together to advance colore**al cancer treatment.
For additional information, please visit:
www.rand-biotech.com
